Ziv-Aflibercept receives FDA approval for colorectal cancer

The U.S. Food and Drug Administration (FDA) has approved a new drug to treat metastatic colorectal cancer.  Ziv-Aflibercept (ZALTRAP) is used in combination with FOLFIRI as a second-line treatment for patients with stage IV colorectal cancer, blocking "the formation of new blood vessels for fast-growing tumors." 

To read more about the trial results leading to FDA approval, click here.